Anti-TNF therapy

Benefits

Risk

Overtime:
SHOW:
grid-1
grid-1

Benefit

Harm

Study overview

  • Figure shows absolute benefit/risk. This is calculated by assessing benefit/risk of study drug against placebo, except where stated
  • Multicenter, double-blind, randomized, placebo-controlled trial
  • Evaluated the efficacy of infliximab maintenance therapy in 306 adult patients with Crohn's disease and one or more draining abdominal or perianal fistulas of at least three months' duration
  • Patients received 5 mg of infliximab per kilogram of body weight intravenously on weeks 0, 2, and 6
  • 195 patients who had a response at weeks 10 and 14 (initial responders) and 87 patients who had no response (initial non-responders) were then randomly assigned to receive placebo or 5 mg of infliximab per kilogram every eight weeks and to be followed to week 54

Terms and conditions

By using this site you acknowledge that the content of this website is based on a review process of the ECCO Consensus Guidelines and primarily aims at facilitating their visualization.

Any treatment decisions are a matter for individual clinicians and may not be based primarily on the e-Guide content.

The European Crohn's and Colitis Organisation and/or any of its staff members and/or any website contributor may not be held liable for any information published in good faith on this website.

You agree that the use of this website is at your own risk and hereby waive any and all potential claims against European Crohn's and Colitis Organisation, and/or any of its staff members and/or any of the website contributors.